ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug ...

(RTTNews) - Johnson & Johnson (JNJ) reported data from the Phase 3 ASTRO study of TREMFYA subcutaneous induction therapy in adults with moderately to severely active ulcerative colitis. The ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...

Local philanthropists Larry Sears and Sally Zlotnick Sears awarded a “transformative” $1 million gift to the Crohn’s & ...

A preliminary modeling study suggests that four variables accessible at discharge could predict the risk for 90-day ...